{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:19:33Z","timestamp":1783487973983,"version":"3.55.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Cystic fibrosis (CF) is one of the most common genetic diseases with around 70,000 affected patients worldwide. CF is a multisystem disease caused by a mutation in the CF transmembrane conductance regulator gene, which has led to a significant decrease in life expectancy and a marked impairment in the quality of life for people with CF (pwCF). In recent years, the use of highly effective CFTR modulator therapy (HEMT) has led to improved pulmonary function, fewer CF exacerbations, lower symptom burden, and increased weight. This has coincided with an increased life expectancy for pwCF, with mean age of survival being now in the 50s. This being a major breakthrough, which the CF population has hoped for, pwCF are now facing new challenges by growing old with a chronic respiratory disease. In this mini review, we are attempting to summarize the current knowledge of the aging process and its effect on CF disease and its manifestations including new developments, the current research gaps and potential future developments in the field to allow healthy aging for the CF community.<\/jats:p>","DOI":"10.3389\/fmed.2023.1340388","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:31:11Z","timestamp":1704691871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["What the future holds: cystic fibrosis and aging"],"prefix":"10.3389","volume":"10","author":[{"given":"Sydney","family":"Blankenship","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Landis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Harrison Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacelyn E.","family":"Peabody Lever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Krick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1146\/annurev.physiol.67.032003.154107","article-title":"Assembly of functional CFTR chloride channels","volume":"67","author":"Riordan","year":"2005","journal-title":"Annu Rev Physiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14728222.2018.1501361","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease","volume":"22","author":"Moore","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"ref4","volume-title":"Patient registry 2021 annual data report","year":"2021"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fendo.2018.00020","article-title":"Cystic fibrosis-related diabetes","volume":"9","author":"Kayani","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2002288","DOI":"10.1183\/13993003.02288-2020","article-title":"Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study","volume":"58","author":"McKone","year":"2021","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1183\/09031936.00059814","article-title":"Ageing and the epidemiology of multimorbidity","volume":"44","author":"Divo","year":"2014","journal-title":"Eur Respir J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1183\/09031936.00186914","article-title":"Hallmarks of the ageing lung","volume":"45","author":"Meiners","year":"2015","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.3390\/ijms21186924","article-title":"Targeting aging pathways in chronic obstructive pulmonary disease","volume":"21","author":"Easter","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","article-title":"High blood pressure and cardiovascular disease","volume":"75","author":"Fuchs","year":"2020","journal-title":"Hypertension"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.2337\/dc12-1801","article-title":"Diabetes in older adults","volume":"35","author":"Kirkman","year":"2012","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3389\/fimmu.2017.01745","article-title":"Aging, obesity, and inflammatory age-related diseases","volume":"8","author":"Frasca","year":"2017","journal-title":"Front Immunol"},{"key":"ref17","first-page":"i","article-title":"Polypharmacy: a global risk factor for elderly people","volume":"6","author":"Dagli","year":"2014","journal-title":"J Int Oral Health"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/cid\/cix203","article-title":"Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study","volume":"64","author":"Somayaji","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S2213-2600(19)30365-0","article-title":"Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study","volume":"7","author":"Wolter","year":"2019","journal-title":"Lancet Respir Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ppul.1950190103","article-title":"Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis","volume":"19","author":"Pamukcu","year":"1995","journal-title":"Pediatr Pulmonol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway Bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0145422","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microbiol Spectr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e0314821","DOI":"10.1128\/mbio.03148-21","article-title":"Combining Ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections","volume":"12","author":"Durfey","year":"2021","journal-title":"MBio"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1378\/chest.115.5.1321","article-title":"Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia","volume":"115","author":"Fraser","year":"1999","journal-title":"Chest"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<93::AID-PPUL4>3.0.CO;2-O","article-title":"Left ventricular perfusion deficit in patients with cystic fibrosis","volume":"25","author":"de Wolf","year":"1998","journal-title":"Pediatr Pulmonol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/j.jcf.2016.09.010","article-title":"Coronary artery disease in cystic fibrosis: an emerging concern?","volume":"15","author":"Skolnik","year":"2016","journal-title":"J Cyst Fibros"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1258\/jrsm.2010.s11010","article-title":"Ischaemic heart disease--a new issue in cystic fibrosis?","volume":"103","author":"Perrin","year":"2010","journal-title":"J R Soc Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.freeradbiomed.2014.08.005","article-title":"Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis","volume":"76","author":"Reverri","year":"2014","journal-title":"Free Radic Biol Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/MCP.0b013e32833e8700","article-title":"Update on cystic fibrosis-related diabetes","volume":"16","author":"Stecenko","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1002\/ppul.23762","article-title":"CF-related diabetes: containing the metabolic miscreant of cystic fibrosis","volume":"52","author":"Moheet","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"702823","DOI":"10.3389\/fendo.2021.702823","article-title":"The potential causes of cystic fibrosis-related diabetes","volume":"12","author":"Coderre","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e14958","DOI":"10.1111\/dme.14958","article-title":"Mediation of the total effect of cystic fibrosis-related diabetes on mortality: a UK cystic fibrosis registry cohort study","volume":"39","author":"Tanner","year":"2022","journal-title":"Diabet Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","article-title":"Genetics of diabetes mellitus and diabetes complications","volume":"16","author":"Cole","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.3390\/ijms21082891","article-title":"Cystic fibrosis, CFTR, and colorectal Cancer","volume":"21","author":"Scott","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.healun.2021.04.011","article-title":"Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients","volume":"40","author":"Shah","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/jnci\/djs481","article-title":"Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States","volume":"105","author":"Maisonneuve","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.3748\/wjg.v25.i38.5732","article-title":"Role of ion channels in gastrointestinal cancer","volume":"25","author":"Anderson","year":"2019","journal-title":"World J Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcf.2016.07.011","article-title":"Cancer risk among lung transplant recipients with cystic fibrosis","volume":"16","author":"Fink","year":"2017","journal-title":"J Cyst Fibros"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.gastro.2017.12.012","article-title":"Cystic fibrosis colorectal cancer screening consensus recommendations","volume":"154","author":"Hadjiliadis","year":"2018","journal-title":"Gastroenterology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J Transl Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor \/ ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"100276","DOI":"10.1016\/j.jcte.2021.100276","article-title":"Obesity in cystic fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PTS.0b013e3181a551ed","article-title":"Risk factors for falling among community-based seniors","volume":"5","author":"Fletcher","year":"2009","journal-title":"J Patient Saf"},{"key":"ref54","year":""},{"key":"ref55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1471-2466-14-205","article-title":"Symptoms of depression impact the course of lung function in adolescents and adults with cystic fibrosis","volume":"14","author":"Fidika","year":"2014","journal-title":"BMC Pulm Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e019305","DOI":"10.1136\/bmjopen-2017-019305","article-title":"Online versus paper-based screening for depression and anxiety in adults with cystic fibrosis in Ireland: a cross-sectional exploratory study","volume":"8","author":"Cronly","year":"2018","journal-title":"BMJ Open"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jpsychores.2018.11.016","article-title":"Positive mental health and wellbeing in adults with cystic fibrosis: a cross sectional study","volume":"116","author":"Cronly","year":"2019","journal-title":"J Psychosom Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the Management of Depression and Anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"100280","DOI":"10.1016\/j.jcte.2021.100280","article-title":"Eating disorders and body image in cystic fibrosis","volume":"26","author":"Darukhanavala","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"ref60","first-page":"36","article-title":"The nature and prevalence of eating disorders and eating disturbance in adolescents with cystic fibrosis","volume":"97","author":"Shearer","year":"2004","journal-title":"J R Soc Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3945\/an.112.003608","article-title":"Chronic illness and disordered eating: a discussion of the literature","volume":"4","author":"Quick","year":"2013","journal-title":"Adv Nutr"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International committee on mental health in cystic fibrosis: Cystic Fibrosis Foundation and European cystic fibrosis society consensus statements for screening and treating depression and anxiety","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ppul.24311","article-title":"Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis","volume":"54","author":"Friedman","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.chest.2016.11.009","article-title":"Cystic fibrosis and the nervous system","volume":"151","author":"Reznikov","year":"2017","journal-title":"Chest"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12967-021-03092-x","article-title":"Regional brain tissue changes in patients with cystic fibrosis","volume":"19","author":"Roy","year":"2021","journal-title":"J Transl Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1542\/peds.113.6.1549","article-title":"Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition","volume":"113","author":"Koscik","year":"2004","journal-title":"Pediatrics"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"111725","DOI":"10.1016\/j.nut.2022.111725","article-title":"Improving nutrition in cystic fibrosis: a systematic literature review","volume":"102","author":"Mielus","year":"2022","journal-title":"Nutrition"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor improves exercise capacity in adolescents with cystic fibrosis","volume":"57","author":"Causer","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12890-015-0151-7","article-title":"Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis","volume":"15","author":"Savi","year":"2015","journal-title":"BMC Pulm Med"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01823246-200819040-00002","article-title":"Perceptions of physical activity in a Group of Adolescents with cystic fibrosis","volume":"19","author":"Swisher","year":"2008","journal-title":"Cardiopulm Phys Ther J"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1378\/chest.116.3.647","article-title":"Hypoxemia and hypercapnia during exercise and sleep in patients with cystic fibrosis","volume":"116","author":"Bradley","year":"1999","journal-title":"Chest"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":"The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: current knowledge and future directions","volume":"18","author":"Putman","year":"2019","journal-title":"J Cyst Fibros"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"CD002010","DOI":"10.1002\/14651858.CD002010.pub5","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","volume":"2014","author":"Conwell","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1340388\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:31:16Z","timestamp":1704691876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1340388\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":74,"alternative-id":["10.3389\/fmed.2023.1340388"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1340388","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1340388"}}